Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Update

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 8,500 shares, a growth of 214.8% from the November 30th total of 2,700 shares. Based on an average trading volume of 898,500 shares, the short-interest ratio is currently 0.0 days.

Provectus Biopharmaceuticals Stock Down 0.4 %

Provectus Biopharmaceuticals stock traded down $0.00 during midday trading on Friday, hitting $0.12. 29,945 shares of the stock were exchanged, compared to its average volume of 255,003. The company has a fifty day simple moving average of $0.12 and a two-hundred day simple moving average of $0.11. Provectus Biopharmaceuticals has a 52 week low of $0.04 and a 52 week high of $0.22.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.